U.S. License Holder:
Ipsen Biopharm Ltd.
Date of License:
April-29-2009
Last Update:
January-15-2021
FDA-Approved Indications
DYSPORT (abobotulinumtoxinA) is an acetylcholine release inhibitor and a neuromuscular blocking agent indicated for:
The treatment of cervical dystonia in adults;
The temporary improvement in the appearance of moderate to severe glabellar lines associated with procerus and corrugator muscle activity in adult patients greater than 65 years of age;
The treatment of upper and lower limb spasticity in adults;
The treatment of upper limb spasticity in pediatric patients 2 years of age and older, excluding spasticity caused by cerebral palsy;
The treatment of lower limb spasticity in pediatric patients 2 years of age and older.